Regulation of Nanotechnology in Food Craig Simpson, Attorney 14 June 2007.

Slides:



Advertisements
Similar presentations
Risk Assessment. Objectives By the end of this presentation you will know: What risk assessment is; Where the need for risk assessment comes from; and.
Advertisements

EPAA Annual Conference Regulatory acceptance and implementation of 3Rs approaches Plant protection products Patricia Brunko European Commission - DG SANCO.
Andrej Kobe EP Brussels, 21 November 2011
Domestic Import Regulations for GMOs and their Compatibility with WTO Rules: Some Key Issues Heike Baumüller ICTSD Trade and Development Symposium
Canada/Australia Issues being faced in the regulation of nano-materials Deborah Willcocks – Department of Health and Ageing, Government of Australia Anne-Marie.
1. European Commission Status GHS Implementation in the European Community Global Thematic Workshop on Strengthening Capacities to Implement the GHS Johannesburg.
Health and Safety Executive Regulator’s expectation in implementation of comparative assessment Jayne Wilder Chemicals Regulation Directorate, Health and.
Outline What is the precautionary principle? Precautionary principle in the context of DSM Obligation to apply the precautionary approach Precautionary.
Additives and Contaminants (incl. Flavourings, Extraction Solvents, Enzymes and Ionising Radiation) 30 March 2011.
Forsigtighedstilgang – gevinst eller stopklods Precautionary Principle good or bad for innovation Bjorn Gaarn Hansen Head of Unit: Chemicals Directorate:
Interpretation of precaution in CEE countries – use it or abuse it? Liina Eek Ministry of Environment, Estonia 18 April 2006 Vienna.
Hogan Lovells EU Product Safety and Market Surveillance Reforms How will this impact businesses – Lawyers' view BIICL seminar, 2 October.
Regulation, Law and Animal Health and Welfare The role of legal regulation GOLD John McEldowney, School of Law, University of Warwick.
Columbia University IRB IRB 101 September 21, 2005 George Gasparis, Executive Director, CU IRB Asst. V.P. and Sr. Asst. Dean for Research Ethics.
Chemicals Management in a Transatlantic Perspective Henrik Selin November 10, 2008.
Nanotechnology: an integrated product policy approach Rosalind Malcolm Professor of Law School of Law University of Surrey UK.
Rapid Alert System for Food and Feed
Regulatory Body MODIFIED Day 8 – Lecture 3.
Frequently Asked Questions (FAQ) prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9.
Integration of Regulatory Impact Assessment into the decision making process in the Czech Republic Aleš Pecka Department of Regulatory Reform and Public.
Nano-Safety: Some Future Perspectives Conference on Nano-Safety April, Slovenia, Ljubljana Bjorn G. Hansen dHoU Chemicals, DG ENV, European Commission.
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
ICONN DEEWR Nanotechnology OHS Research and Development Program & Nanotechnology OHS Regulation Dr Howard Morris Nanotechnology OHS R&D Program.
IPhVWP Polish Presidency, Warsaw October 6 th 2011 Almath Spooner Irish Medicines Board Monitoring the outcome of risk minimisation activities.
Clinical Research Conference 2012 Legal, Ethical, and Social Dimensions of Clinical Research Takis Vidalis, Ph. D., Hellenic National Bioethics Commission.
The Precautionary Principle in EU Food Law 15 November 2004 by Craig Simpson, Brussels EU Regulatory Practice.
Nanotechnology The Regulatory Landscape for the Food Industry
EXAMPLES OF TECHNICAL BARRIERS TO TRADE  one of the main TBT issue at the moment is labelling (see Tuna report)  brief overview of marks and rules of.
The Swiss Action Plan on Synthetic Nanomaterials: State of implementation Georg Karlaganis Regional Nano Workshop for Asia Pacific Bangkok Thailand 10.
Presentation 4: How can I know if nanomaterials are used in my workplace?
Nanosciences and nanotechnologies: European Action
The Precautionary Principle in the Sweden, the EU and the US Comparative Risk Regulation Workshop at University of California, Berkeley December
1 GIE Annual Conference Madrid, November 2007 Investing in Europe‘s Future – the Role of Regulators David Halldearn Senior Adviser, European Affairs.
Environment Committee Issues Corina Hebestreit The Barytes Association 16 November 2005.
Main Requirements on Different Stages of the Licensing Process for New Nuclear Facilities Module 4.1 Steps in the Licensing Process Geoff Vaughan University.
Nanomaterials classification and labelling – status of work undertaken in GHS (Globally Harmonized System of Classification and Labelling of Chemicals)
Advisory group on fruit and vegetables 7 March 2008
1 Risk Governance of Manufactured Nanoparticles, Joint Workshop EP STOA Panel – European Commission, Brussels, 21 November 2011 Interfaces between Science.
RISK MANAGEMENT The process of weighing policy alternatives in the light of the results of risk assessment and, if required, selecting and implementing.
Module 3 Risk Analysis and its Components. Risk Analysis ● WTO SPS agreement puts emphasis on sound science ● Risk analysis = integrated mechanism to.
Keller and Heckman LLP Market Access and Trade Barriers and Practices: The Role of the Precautionary Principle and Other Non-Scientific Factors in Regulating.
EPA essential principles for reform of chemicals management legislation – lessons from REACH Dr Veerle Heyvaert London School of Economics Chemical Regulation:
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Regulatory Authority.
Directorate General for Enterprise and Industry European Commission The New Legislative Framework - Market Surveillance UNECE “MARS” Group meeting Bratislava,
Data protection and compliance in context 19 November 2007 Stewart Room Partner.
Nanomaterials: UK experience and SAICM relevance Richard Vincent Head of International Chemicals and Nanotechnologies, Defra WEOG Regional Focal Point.
The EU Directive on "Services in the internal market", COM(2004) 2 final/3 Agnese Knabe Project coordinator European Public Health Alliance Civic Alliance.
The New Legislative Framework
Implementation of the CHP Directive - overview and outlook Talking competitiveness! New perspectives for CHP/DHC EHP Annual Conference Brussels
IMPLEMENTING MEASURES GM FOOD – FEED REGULATION (EC) N° 1829/2003 -Articles 5 and 17 concerning the presentation and preparation of the application -Articles.
Health and environmental impacts of nanoparticles: too early for a risk assessment framework? Prof Jim Bridges Emeritus Professor of Toxicology and Environmental.
EU Plant Health Regime - Role of research -Evaluation of EU PLH Regime Guillermo H. Cardon European Commission, DG SANCO Plant health / Harmful organisms.
Edible insects and missing legislation: the EU outlook 1. ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLE VENEZIE, Legnaro (PD), ITALY
Date: in 12 pts MARKET SURVEILLANCE IN THE EU ROLE IN THE NLF - EU ACTIONS and DEVELOPMENTS Rita L'Abbate European Commission DG ENTERPRISE AND INDUSTRY.
Principles in international environmental law April 30, 2014 Edmunds Broks.
IADSA SCIENTIFIC FORUM, MOSCOW, June 2009 The European Union Perspective on Risk/Benefit Professor Dr. Arpad Somogyi Berlin - Brussels - Budapest.
1 Package on food improvement agents Food additives Food enzymes Flavourings Common procedure Developments since earlier consultation.
66 items – 70% of circulated products
FDA’s IDE Decisions and Communications
The New Legislative Framework Miniseminar New Legal Framework Reykjavík, 10 December 2008 Doris Gradenegger Unit C1: Regulatory Approach for the Free.
EU-OSHA Workshop: Workplace Risks to Reproductive Function
The EU‘s ‚participatory‘ authorisation process for GMOs
Multinational collaboration in the Authorisation of VMPs: the EU approach VICH Outreach Forum Tokyo, Nov 2017 Noel Joseph European Commission.
Vytenis Andriukaitis European Commissioner for Health and Food Safety
The Mutual Recognition Regulation
CCMI 9 September 2015 Public Hearing: Nanotechnology for a competitive chemical industry Social aspects: education, health and safety.
EU action after Deepwater Horizon accident - Gulf of Mexico – April 2010
Institutional changes The role of Bilateral Oversight Boards
Revision of Decision 2010/477/EU
Presentation transcript:

Regulation of Nanotechnology in Food Craig Simpson, Attorney 14 June 2007

OUTLINE 1.Applications of Nanotechnology in the Food Area 2.Current EU Regulation of Nanotechnology in Food 3.Problems with Current Regulatory Framework 4.The Problem of Risk Assessment 5.Options for Future Regulation 6.The US Perspective – Potential for a Trade Dispute à la GMO?

APPLICATIONS OF NANOTECHNOLOGY IN FOOD  Food Packaging ‘Active’ or ‘intelligent’ packaging  Food Processing: Taste and Texture For example, nanoparticle emulsions to improve texture (trickling agents) and reduce fat content  Functional Foods Nanocapsules enclosing nutrients such as vitamins or Omega 3 fatty acids (‘nanoceuticals’) for release into body when required

CURRENT REGULATION OF NANOTECHNOLOGY IN FOOD  No dedicated EU or US legislation (for food or otherwise)  Indirect regulation of products or processes incorporating nanotechnology, not of nano- technology component itself  Existing ‘precautionary approach’ prior approval food legislation (process/product specific) For example: Novel Foods (Regulation 258/97) Food Additives (Directive 89/107, and daughter directives on specific purity criteria)

CURRENT REGULATION OF NANOTECHNOLOGY IN FOOD Food contact materials (Regulation 1935/2004 and daughter Directives on specific materials) Food supplements (Directive 2002/46) Fortification (Regulation 1925/2006)  Non-food specific chemicals prior approval legislation: REACH (Regulation 1907/2006) since 1 June 2007 Dangerous Substances Directive (Directive 67/548) (largely replaced by REACH)  General principle of food law: ‘Food shall not be placed on the market if it is unsafe’ (Article 14(1), Regulation 178/2002)

PROBLEMS WITH CURRENT LAW Summary of Conclusions of Report of UK FSA Regulatory Review EU LegislationGaps in Regulation Novel Foods (Regulation 258/97) – mandatory pre-market approval for all novel foods and processes – Adequate for new nanomaterials: measures toxicology and considers manufacturing process – Inadequate for new nanoversions of ingredients Food Additives (Directive 89/107 and implementing legislation) – Positive lists, maximum levels, specific purity criteria – Inadequate since generally no control of particle size – Purity criteria Directives could be easily amended by comitology to include minimum particle size provision Food Contact Materials (Regulation 1935/2004 and implementing legislation) – Controls migration of chemicals from materials into food – Inadequate: no differentiation between ‘routine’ chemicals and those produced by nanotechnology – Suggests amending Regulation 1935/2004 to require nanocomponents to be subject to own risk assessment (regardless of the material incorporated into)

PROBLEMS WITH CURRENT LAW  Prior Approval Legislation: Report of UK FSA Regulatory Review re current regulation of nanotechnology in food (March 2006) Does not cover all nanotechnology uses: ‘most potential uses of nanotechnologies that could affect the food area would come under some form of approval process before being permitted for use’ (para. 62) Does not require testing of new nanotechnology versions of ingredients/ materials already on positive list (not previously checked for particle size): ‘uncertainty in some areas whether application of nanotechnologies would be picked up consistently’ (para. 63)

PROBLEMS WITH CURRENT LAW  REACH Substances used in foods (including additives and flavourings) largely exempted (Article 2(5)(b) Substances in food contact materials and food additives and flavourings preparations sold as such to final user covered (Articles 2(6)(d) and 14(5)(a)) 1 ton threshold suitable for nanoparticles? Lack of risk assessment method?: ‘...methodologies for identifying hazards and evaluating risks of substances at the nano-scale need to be further refined over the next few years...’

PROBLEMS WITH CURRENT LAW ‘It will also be necessary to carefully monitor over the next few years whether the 1t threshold for registration and the information requirements under REACH are adequate to address potential risk from particles on a nano-scale’ (REACH Q&A)  No marketing of unsafe food ‘Unsafe’ subjective decision of food business operator When is duty to recall (Article 19) triggered?  General Conclusion: Current legislation unsuited to specifics of nanotechnology and rarely used Significant that no notification for nanotechnology applications made under Directive 67/548

RISK ASSESSMENT OF NANOTECHNOLOGY  Clear that not yet possible to carry out a risk assessment of nanoparticles Commission Communication on Nanotechnology (May 2004): need to ‘generate the data needed for risk assessment.’ SCENIHR Opinion on Nanotechnology (September 2005): ‘major gaps in the knowledge necessary for risk assessment’. EFSA Note on Nanoscience (March 2006): ‘It is clear that for future risk assessment of nanoparticles additional information, knowledge and tools are needed, e.g. –investigation of the mechanism and toxicological potential –reconsideration of the currently applied paradigms for risk assessment in the light of the altered properties of nanoparticles –development and allocation of analytical tools to monitor the occurrence and distribution of nanoparticles’. EFSA 2007 Management Plan: develop harmonised risk assessment approaches and gather more data for further analysis

HOW TO REGULATE NANOTECHNOLOGY IN THE EU IN THE FUTURE  EFSA State of Play (2006): ‘most countries are still in the phase of raising awareness and investigating what the regulated topics should be’.  Commission favours proactive amendment of existing EU prior approval Regulations only Communication (2004): ‘Maximum use should be made of existing regulation. However, the particular nature of nanotechnologies requires their re-examination and possible revision.’ (para ) Action Plan (2005): ‘propose adaptations of EU regulations in relevant sectors...’ (para. 6.1(d))  Amend specific additive purity criteria Directives through comitology to include minimum particle size

HOW TO REGULATE NANOTECHNOLOGY IN THE EU IN THE FUTURE  Food Additives Proposal Evaluation of new nanotechnology versions of additive already approved (Recital 13) EP ENVI Committee Report on Proposal: separate limit values for nanoparticles in additives and treat separately on positive list (Amendment 35) Faster authorisation procedure for new additives: Commission decision based on EFSA risk assessment and technological need/ consumer interest assessment of SCFAH

HOW TO REGULATE NANOTECHNOLOGY IN THE EU IN THE FUTURE  Moratorium/Ban on nanotechnology products Green support: Australian lobby group, Greenpeace Communication (2004): moratorium ‘severely counter- productive’ (para ) Breach of Article 5.1 of WTO SPS Agreement if prior to full risk assessment (WTO Beef Hormones ruling 1999 and EC- Biotech Products ruling 2006 re safeguard measures)  Ban based on precautionary principle? Communication (2004): ‘The Precautionary Principle... could be applied in the event that realistic and serious risks are identified.’ (para ) Article 5.7 SPS: ‘...on the basis of available pertinent information, including that from the relevant international organisations...’

HOW TO REGULATE NANOTECHNOLOGY IN THE EU IN THE FUTURE Article 7 Regulation 178/2002: ‘the possibility of harmful effects on health if identified but scientific uncertainty persists...’ German Federal Institute for Risk Assessment (BfR) Draft Nanotechnology Research Strategy August 2006: –‘the risks have not yet been characterised’ –‘we do not know whether there are any risks involved in the uptake of nanoparticles from the gastro-intestinal tract’ (Reported in EU Food Law, November 24, 2006) Alpharma case (T-70/99): ‘a preventive measure [based on the precautionary principle] cannot be based on a purely hypothetical approach to risk, founded on mere conjecture which has not been verified’ (para. 156)

THE NEXT TRANSATLANTIC TRADE DISPUTE?  Inevitable comparisons to GMO US-EU trade dispute: strategic economic value v. societal fears  Current regulatory position in EU and US very similar: indirect regulation only, in practice none  FDA more defensive ‘head in sand’ approach than EU, reactive not proactive: ‘FDA believes that the existing battery of pharmatoxicity tests is probably adequate for most nanotechnology products that we will regulate. Particle size is not the issue... FDA regulates products, not technology.’ (FDA and Nanotechnology Products FAQs)

THE NEXT TRANSATLANTIC TRADE DISPUTE? International Centre for Technology Assessment (CTA) petitions FDA May 2006: Amendment of regulations to require new nano-specific testing and mandatory product labelling  Likelihood of EU-US trade dispute? Future EU moratorium or national safeguard measures? Will US follow ‘non-product incorporated’ product distinction approach in GMO debate? (does not recognise product distinctions based on production processes and methods (‘PPMs’) not reflected in the final characteristics of a good)

THE NEXT TRANSATLANTIC TRADE DISPUTE?  Difference may be real health risk: US may take process based approach in common with EU Avoid conflict over EU precautionary measures based mainly on societal considerations –‘Scientific risk assessment alone cannot, in some cases, provide all the information on which a risk management decision should be based, and other factors relevant to the matter under consideration should be legitimately be taken into account including societal [and] ethical factors’ (Regulation 178/2002, Recital (19), Article 7.2)

CONCLUSIONS 1.EU Regulation currently insufficient and not used in practice. Lack of risk assessment capabilities a major reason for this. 2.Commission proactive approach to amendment of current food safety legislation. No dedicated GMO style legislation anticipated. 3.Precautionary measures possible but seem unlikely, and not legally justifiable, for the moment. 4.US position less proactive, more reactive product based approach – but public pressure to fill regulatory void. 5.Likelihood of a trade dispute low: –Commission’s wish to avoid repeat of GMO; and –real risks more likely to be identified.